EU/3/19/2245

Table of contents

About

On 9 January 2020, orphan designation EU/3/19/2245 was granted by the European Commission to TMC Pharma (EU) Limited, Ireland, for setmelanotide for the treatment of Alström syndrome.

The sponsorship was transferred to Rhythm Pharmaceuticals Limited, Ireland, in November 2020.

Key facts

Active substance
Setmelanotide
Disease / condition
Treatment of Alström syndrome
Date of first decision
09/01/2020
Outcome
Positive
EU designation number
EU/3/19/2245

Sponsor's contact details

Rhythm Pharmaceuticals Limited
10 Earlsfort Terrace 
Dublin 2  
D02 T380 
Co. Dublin 
Ireland
E-mail: regulatory.services@tmcpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating